CCL2 and kidney disorder: Other evidence has demonstrated that A20 could realistically improve the outcomes in kidney disease with A20 protein exerting potent NF-κB inhibitory effects in renal proximal tubular epithelial cells, shutting down the up-regulation of pro-inflammatory molecules such as both MCP-1 and ICAM-1 [31].